Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of SGLT2 Inhibitors on Anemic CKD Patients
Sponsor: Sohag University
Summary
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD
Official title: Effect of SGLT2 Inhibitors On Anemia in Patients With Chronic Kidney Disease (CKD)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2026-01-01
Completion Date
2026-09-01
Last Updated
2026-01-14
Healthy Volunteers
Yes
Conditions
Interventions
SGLT2 inhibitor
prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4
Locations (1)
Sohag University Hospital
Sohag, Sohag University, Egypt